BRIEF—Bristol-Myers presents colorectal cancer data at ESMO

Bristol-Myers Squibb has presented results showing Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) achieved a 60% objective response rate in certain patients with previously untreated metastatic colorectal cancer.

The data from the CheckMate -142 trial were revealed at the European Society of Medical Oncology annual congress.

The data also supported the durability of the combo. At the cut-off point, median duration of response had not yet been reached and 82% of responding patients had ongoing responses.

Co-lead investigator Heinz-Josef Lenz said: “Today’s results from CheckMate -142 underscore the durability of Opdivo plus low-dose Yervoy in metastatic colorectal cancer patients whose tumors express MSI-H or dMMR biomarkers, and show the potential for this combination as a first-line treatment for these patients, who typically experience poor treatment outcomes.”